Strides Arcolab has received ANDA approval from the United States Food & Drug Administration (US FDA) for Imiquimod cream. According to IMS data, the US market for generic Imiquimod cream is approximately $140 million. This is the first product approval from Beltapharm, the company’s US FDA approved semi solids facility in Milan, Italy. The product will be marketed directly by Strides in the US Market.
EP News Bureau-Mumbai